Micafungin: pharmacology, experimental therapeutics and clinical applications (Q36120798)

12 August 2017

1 reference

title

Micafungin: pharmacology, experimental therapeutics and clinical applications (English)

1 reference

12 August 2017

1 reference

3

Emmanuel Roilides

1 reference

12 August 2017

4

Thomas J Walsh

1 reference

12 August 2017

Theodouli Stergiopoulou

object named as

Theodouli Stergiopoulou

series ordinal

2

1 reference

ORCID Public Data File 2021

author name string

Andreas H Groll

series ordinal

1

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 April 2005

1 reference

Expert Opinion on Investigational Drugs

12 August 2017

published in

1 reference

12 August 2017

volume

14

1 reference

12 August 2017

issue

4

1 reference

12 August 2017

page(s)

489-509

1 reference

Morphological changes of Candida albicans induced by micafungin (FK463), a water-soluble echinocandin-like lipopeptide

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.489

Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.489

Killing activity of micafungin against Aspergillus fumigatus hyphae assessed by specific fluorescent staining for cell viability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.489

Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.489

In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.489

In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.489

In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.489

In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.489

In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.489

In vitro activities of new antifungal agents against Chaetomium spp. and inoculum standardization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.489

A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.489

Effect of Micafungin (FK463) on Candida albicans adherence to epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.489

Comparison of two methods and three end points in determination of in vitro activity of micafungin against Aspergillus spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.489

Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.489

Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.489

Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.489

Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.489

Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.489

Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant candida albicans infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.489

In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.489

Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.489

Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.489

Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.489

Prophylactic effect of FK463, a novel antifungal lipopeptide, against Pneumocystis carinii infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.489

Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.489

A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.489

A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.489

Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.489

10.1517/13543784.14.4.489

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference